Thus the expression is not confined to malignant B cells but 
Immunophenotyping was performed by routine immunohistochemistry on frozen or paraffin sections, and/or flow cytometry on cell suspensions. In follicle center cell (FCC)-derived Introduction NHL the neoplastic origin of B cell follicles was further confirmed by staining with antibody to BCL2 protein (Dakopatts, Chromosomal rearrangements of LAZ3/BCL6, a recently ident-Ä lvsjö, Sweden) and avidin-biotin-immunoperoxidase method ified gene on chromosome 3, band q27, [1] [2] [3] are detectable in (ABC Vectastain Kit; Vector Laboratories, Burlingame, CA, 20-30% of diffuse large-cell B cell lymphomas. 4, 5 This gene USA). The proliferative fraction was evaluated by immunoencodes a 79 kDa protein that contains six Cys2-His2 zink staining with antibody to proliferating cell nuclear antigen fingers in its C-terminal portion and shares amino-terminal (PCNA, PC10; Dakopatts) and ABC technique as previously homology with a number of transcriptional regulators, includdescribed. 11 All histopathology slides were evaluated by an ing the Drosophila tramtrack and Broad-complex genes, 1,2 but independent investigator without knowledge of the in situ its exact function remains uncertain. However, it has been hybridization results. shown that LAZ3/BCL6 could be involved in the process of chromatin folding. 6, 7 Originally, LAZ3/BCL6 was described as predominantly expressed in skeletal muscle 2 and activated in B cell lymphomas through translocation to a different promoNorthern blot hybridization tor. Later, LAZ3/BCL6 expression was also detected in nonrearranged B cell lymphomas. 8 This suggested that the Commercial human multiple-tissue Northern blots (Clontech, LAZ3/BCL6 gene had a more general role than anticipated, Palo Alto, CA, USA), containing poly(A)+ RNA from in total and prompted us to perform an expression analysis on 23 different tissues were hybridized, in subsequent hybridizamultiple tissues.
tions, with the two antisense synthetic oligonucleotides used In order to determine if the LAZ3/BCL6 expression is related in the in situ hybridization studies. The probes were 3′-end to lymphomagenesis we extended the analysis to study the labeled with ␣ 32 P-ATP (DuPont/NEN, Boston, MA, USA; expression pattern of LAZ3/BCL6 with RNA in situ hybridiz-NEG012H) using terminal deoxynucleotidyl transferase (IBI, ation on a series of non-malignant reactive lymph nodes and New Haven, CT, USA). The hybridization was performed at non-Hodgkin lymphomas (NHL). Our data clearly show that 50°C in 5 × SSC, 1% SDS, 0.1 mg/ml salmon sperm DNA, 5% LAZ3/BCL6 is expressed in follicular center B cells of both dextran sulfate for 16 h. The filters were washed twice with non-malignant reactive lymph nodes and FC-derived NHLs.
2 × SSC/0.1% SDS at room temperature for 30 min, followed by two washes with 0.5 × SSC/0.1% SDS at 65°C for 15 min. Subsequently, they were exposed for 1-3 days and analyzed scripts, the Northern blots were rehybridized with the GAPDH oligonucleotide probe that was used in the in situ hybridization studies (conditions as above).
In situ hybridization
The in situ hybridization was performed as previously described. 12 Briefly, transverse sections (14 m) were cut in a cryostat (Microm, Heidelberg, Germany), thawed onto ProbeOn slides (Fisher Scientific, Pittsburgh, PA, USA) and stored in black sealed boxes at −70°C until used. For in situ hybridization of the lymph nodes, we used synthetic oligonucleotides complimentary to mRNA encoding human LAZ3/BCL6 GTG TCCGGCC and CTCCACCACC TCACGACCCC GAT-AGGCCAT GATGTCTTGG GGC corresponding to position 23-69 and 534-576 in the cDNA. As a negative control, a 43-mer oligonucleotide, GCCCCAAGAC ATCATGGCCT A weak expression was observed in heart, brain, small intestine, lymph node, adrenal gland and bone marrow, while a ATCGGGGTCG TGAGGTGGTG GAG, sense to the human LAZ3/BCL6 mRNA (cDNA position 534-576) was used. A 45-signal was absent in placenta, lung, liver, kidney, pancreas, spleen, thymus, colon and stomach. The GAPDH hybridizmer oligonucleotide, CGCCCAATAC GACCAAATCC GTTGACTCCG ACCTTCACCT TCCCC specific for the human ation indicated that the spleen lane contained less RNA than the rest of the blot. glyceraldehyde 3-phosphate dehydrogenase (hGAPDH, Acc. No. M33197; cDNA position 63-107), was used a positive control.
The probes were 3′-end labeled with ␣
35
S-ATP (DuPont/NEN; NEG034H) using terminal deoxynucleotidyl Expression studies of lymphoid tissue using in situ hybridization transferase (IBI, USA) and hybridized to the sections without pretreatment for 16-18 h at 42°C. The hybridization mixture contained 50% formamide (GT Baker Chemicals, Deventer,
The histopathological diagnoses and results of the in situ hybridization studies are compiled in Table 1 . The two differThe Netherlands), 4 × SSC (1 × SSC = 0.15 m NaCl and 0.015 m sodium-citrate), 1 × Denhardt's solution (0.02% each ent LAZ3/BCL6 probes gave identical hybridization patterns in all examined tissues, although the oligonucleotide correof polyvinyl-pyrrolidone, BSA and Ficoll), 1% sarcosyl (N-lauroylsarcosine; Sigma, St Louis, MO, USA), 0.02 m phosphate sponding to position 534-576 gave slightly higher background ( Figure 2 ). As an RNA quality control in all cases, we used buffer (pH 7.0), 10% dextran sulfate (Pharmacia, Uppsala, Sweden), 250 g/ml yeast tRNA (Sigma), 500 g/ml sheared GAPDH. 13 Cases 4 and 6 were the only ones in which we did not observe any GAPDH-hybridization, indicating that the and heat denaturated salmon sperm DNA (Sigma) and 200 mm dithiothreitol (DTT; LKB, Bromma, Sweden). Follow-RNA was degraded in this lymph nodes. Therefore, only cases with positive GAPDH-hybridization were considered as ing hybridization the sections were washed several times in 1 × SSC at 55°C, dehydrated in ethanol and dipped in NTB2 evaluable.
In the non-malignant lymph nodes (cases 1-3 and 5) with nuclear track emulsion (Kodak, Rochester, NY, USA). After 3-5 weeks the sections were developed in D-19 developer reactive hyperplasia, we observed a follicular expression pattern of LAZ3/BCL6 that corresponded to the distribution of (Kodak) and cover-slipped. Some of the sections were only exposed to autoradiographic film (Beta-max autoradiography GAPDH expression ( Figure 4C ), that corresponded well to the predominantly diffuse growth patNothern blots hybridized with LAZ3/BCL6 oligonucleotides are shown in Figure 1 . The pattern was compared to GAPDH tern they showed by GAPDH hybridization, and at the histopathological examination (not shown). as ubiquitous expression standard. In those tissues where LAZ3/BCL6 expression was observed, the transcript was A diffuse signal distribution of LAZ3/BCL6 expression was noted in four cases (31-33 and 39) of large cell B cell lymapproximately 3.8 kb, corresponding to the size reported for the normal transcript. 1, 2 In testis, an additional band at 3.0 kb phomas (CB). In two of these cases (31 and 32), a remnant of follicular growth pattern showed FCC origin of lymphoma. In was seen (Figure 1 ). Abundant expression of LAZ3/BCL6 was seen in skeletal muscle, prostate, testis, ovary, peripheral five other studied cases of large cell B cell NHL no LAZ3/BCL6 expression was observed (Nos 34-38). In all nine cases of blood leukocytes, thyroid, spinal cord and trachea (Figure 1 ).
LAZ3/BCL6 expression in follicular center B cells
S Bajalica-Lagercrantz et al 596 Table 1 LAZ3 expression in NHL expression ( Figure 5A ), although a follicular-like pattern of expression was observed using the GAPDH oligo ( Figure 5B ). Here we confirm these findings using in situ hybridization vious publications have also reported LAZ3/BCL6 rearrangements in approximately 30% of diffuse, large cell lymphomas. No positive cases were found among bone marrow B celllarge cell B cell lymphomas the GAPDH expression pattern was diffuse and a high proliferating fraction was found (not derived low-grade lymphocytic lymphomas. Our data confirm that the LAZ3/BCL6 expression is linked shown).
The lymph nodes from two cases of CLL and three cases of to the FCC origin of B cells. This is further corroborated by the findings that there was no correlation between the proliferimmunocytomas (cases 7-11) showed no LAZ3/BCL6 ative activity of studied B cell NHL. The expression of without rearrangements. 8 It has been suggested that small mutations within the control region might be responsible, in GAPDH, on the other hand, followed the same pattern that was seen after proliferation staining, indicating an upregulanalogy to observations in the c-MYC gene. 24 Thus, the role of a dysregulation of the normal LAZ3/BCL6 protein in lymation of GAPDH in proliferating cells. In accordance with previous reports, we did not dectect any LAZ3/BCL6 expression phomagenesis has yet to be investigated. However, the expression of LAZ3/BCL6 in lymphomas may reflect the origin in T cell lymphomas.
Other studies have shown expression of LAZ3/BCL6 in NHL of the tumor rather than the presence of a malignant clone. 
